Cellular immune responses against hepatitis C virus

Clinical Infectious Diseases

Volumn 41, Issue 1 SUPPL., 2005, Pages

  Koziel, Margaret James ^a  

^a HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD8 ANTIGEN; CYTOKINE; FAS LIGAND; OKT 8; RECOMBINANT INTERLEUKIN 10;

CELLULAR IMMUNITY; CHRONICITY; CONVALESCENCE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LIVER DISEASE; LIVER INJURY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUPERINFECTION; T LYMPHOCYTE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; KILLER CELLS, NATURAL; MICE;

EID: 20844447700     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/429492     Document Type: Review

References (81)

1. Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994; 91:7792-6.
2. Norris S, Collins C, Doherty DG, et al. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J Hepatol 1998; 28:84-90.
3. + natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol 1999; 163:2314-21.
4. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003; 300:337-9.
5. Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302:659-62.
6. Missale G, Bertoni R, Lamonaca V, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98:706-14.
7. + T cell response may contribute to the association of HLA-DR13 with viral clearance in hepatitis B. Clin Exp Immunol 1998; 113:244-51.
8. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997; 25:449-58.
9. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6:578-82.
10. Shata MT, Anthony DD, Carlson NL, et al. Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees. J Viral Hepat 2002; 9:400-10.
11. Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002; 99:15661-8.
12. + T-helper-cell responses in resolved hepatitis C virus infection. J Virol 2002; 76:12584-95.
13. + T cell responses in an acutely infected chimpanzee. Hepatology 2003; 38:1297-306
14. [erratum: Hepatology 2003; 38:1602].
15. Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346:1006-7.
16. Lechmann M, Ihlenfeldt HG, Braunschweiger I, et al. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C virus infection and in healthy anti-hepatitis C virus-positive blood donors without viremia. Hepatology 1996; 24:790-5.
17. + T- cell response in acute hepatitis C. Gastroenterology 1999; 117:933-41.
18. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118: 346-55.
19. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194:1395-406.
20. Guidotti LG, Ando K, Hobbs MV, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 1994; 91:3764-8.
21. Greenberg ML, Lacey SF, Chen CH, Bolognesi DP, Weinhold KJ. Non-cytolytic CD8 T cell-mediated suppression of HIV replication. Springer Semin Immunopathol 1997; 18:355-69.
22. + cells. Virology 1996; 225: 248-53.
23. + cells in human immunodeficiency virus type I pathogenesis: cytolytic and noncytolytic inhibition of viral replication. Adv Immunol 1997; 66:273-311.
24. Lanford RE, Guerra B, Lee H, et al. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol 2003; 77:1092-104.
25. + T-cell interaction with HCV replicon cells: evidence for both cytokine- and cell-mediated antiviral activity. Hepatology 2003; 37:1335-42.
26. Cooper S, Erickson AL, Adams EJ, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10:439-49.
27. Erickson AL, Kimura Y, Igarashi S, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001; 15:883-95.
28. + T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197:1645-55.
29. + T cells with viral clearance in acute hepatitis C. J Infect Dis 2000; 181:1528-36.
30. Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191:1499-512.
31. + memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol 2003; 77:4781-93.
32. + T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol 2000; 30:2479-87.
33. + T-cell responsiveness in hepatitis C virus infection. Hepatology 2001; 33:267-76.
34. + T lymphocytes after infection with hepatitis C virus. J Virol 2001; 75:5550-8.
35. + T cells in chronic hepatitis C virus infection. J Immunol 2002; 169:3447-58.
36. Koziel MJ, Dudley D, Wong JT, et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis, J Immunol 1992; 149:3339-44.
37. Koziel MJ, Dudley D, Afdhal N, et al. HLA class 1-restricted cytotoxic T lymphocytes specific for hepatitis C virus, identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 1995; 96:2311-21.
38. + T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci USA 1999; 96:5692-7.
39. + T cells recognize multiple HCV epitopes and produce interferon gamma. Hepatology 2000; 32:597-603.
40. Penna A, Missale G, Lamonaca V, et al. Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: functional characterization in patients with chronic hepatitis C. Hepatology 2002; 35:1225-36.
41. + T-cell response in liver and peripheral blood of hepatitis C virus-infected patients with persistently normal and abnormal alanine aminotransferase levels. J Hepatol 2002; 36:408-16.
42. Grabowska AM, Lechner F, Klenerman P, et al. Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. Eur J Immunol 2001; 31:2388-94.
43. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288:339-44.
44. Weiner AJ, Geysen HM, Christopherson C, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci USA 1992; 89:3468-72.
45. Weiner A, Erickson AL, Kansopon J, et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci USA 1995; 92:2755-9.
46. Wang H, Eckels DD. Mutations in immunodominant T cell epitopes derived from the nonstructural 3 protein of hepatitis C virus have the potential for generating escape variants that may have important consequences for T cell recognition. J Immunol 1999; 162:4177-83.
47. Foy E, Li K, Wang C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300:1145-8.
48. Large MK, Kittlesen DJ, Hahn YS. Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J Immunol 1999; 162:931-8.
49. Bain C, Fatmi A, Zoulim F, Zarski JP, Trepo C, Inchauspe G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 2001; 120:512-24.
50. Lai MM, Ware CF. Hepatitis C virus core protein: possible roles in viral pathogenesis. Curr Top Microbiol Immunol 2000; 242:117-34.
51. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-8.
52. Koziel MJ, Dudley D, Afdhal N, et al. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol 1993; 67:7522-32.
53. + T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med 1993; 178:17-25.
54. + T cell response after liver transplantation occurs early, is multispecific, compartmentalizes to the liver, and does not correlate with recurrent disease. J Infect Dis 2001; 183:1187-94.
55. Erickson AL, Houghton M, Choo QL, et al. Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J Immunol 1993; 151:4189-99.
56. Ward S, Lauer G, Isba R, Walker B, Klenerman P. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol 2002; 128:195-203.
57. + T cell population in chronic hepatitis C virus infection. J Clin Invest 2004; 113:963-72.
58. Pasquinelli C, Shoenberger JM, Chung J, et al. Hepatitis C virus core and E2 protein expression in transgenic mice. Hepatology 1997; 25: 719-27.
59. Kawamura T, Furusaka A, Koziel MJ, et al. Transgenic expression of hepatitis C virus structural proteins in the mouse. Hepatology 1997; 25:1014-21.
60. Wakita T, Katsume A, Kato J, et al. Possible role of cytotoxic T cells in acute liver injury in hepatitis C virus cDNA transgenic mice mediated by Cre/loxP system. J Med Virol 2000; 62:308-17.
61. + murine cytotoxic T lymphocytes in transgenic mice expressing the viral structural genes. Biochem Biophys Res Commun 2003; 301:330-7.
62. Nelson DR, Marousis CG, Davis GL, et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997; 158:1473-81.
63. Locasciulli A, Bacigalupo A, VanLint MT, et al. Hepatitis C virus infection and liver failure in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 16:407-11.
64. + T lymphocytes by murine monoclonal CD8 antibodies and restored specific T cell proliferation in vivo in a patient with chronic hepatitis C. J Immunol 1997; 159:4064-71.
65. Nelson DR, Tu Z, Soldevila-Pico C, et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 2003; 38:859-68.
66. Abrignani S. Bystander activation by cytokines of intrahepatic T cells in chronic viral hepatitis. Semin Liver Dis 1997; 17:319-22.
67. Gremion C, Grabscheid B, Wolk B, et al. Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells via Fas-FasL interaction. J Virol 2004; 78:2152-7.
68. + T cells by flow cytometry: correlation with clinical disease stages. Hepatology 2002; 35:190-8.
69. + T-cell and cytokine response. Gastroenterology 2001; 121:646-56.
70. + T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis. J Infect Dis 2004; 189:1140-50.
71. Rehermann B, Chang KM, McHutchinson JG, Kokka R, Houghton M, Chisari FV. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest 1996; 98:1432-40.
72. Freeman AJ, Pan Y, Harvey CE, et al. The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infection. J Hepatol 2003; 38: 349-56.
73. Wong DK, Dudley DD, Afdhal NH, et al. Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol 1998; 160:1479-88.
74. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34:283-7.
75. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-9.
76. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-13.
77. Valdez H, Anthony D, Farukhi F, et al. Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients. AIDS 2000; 14:2239-46.
78. Lauer GM, Nguyen TN, Day CL, et al. Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol 2002; 76:2817-26.
79. Alatrakchi N, Di Martino V, Thibault V, Autran B. Strong CD4 Th1 responses to HIV and hepatitis C virus in HIV-infected long-term non-progressors co-infected with hepatitis C virus. AIDS 2002; 16:713-7.
80. + T cells in HIV/HCV versus HCV. Hepatology 2004; 40:125-32.
81. + T cell responses to hepatitis C virus (HCV) in the liver of persons with HCV-HIV coinfection versus HCV monoinfection. J Infect Dis 2005; 191:702-9.